Albireo Limited announced that Ron Cooper has joined the company as President and Chief Executive Officer. Mr. Cooper is a global biopharmaceutical leader with a track record of growing businesses, brands and organizations in the U.S. and Europe. He joins Albireo from Bristol-Myers Squibb (BMS), where he was President of Europe.
Albireo Pharma, Inc.
Equities
ALBO
US01345P1066
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+16.34% | 122B | |
+17.45% | 114B | |
+19.62% | 25.71B | |
-25.84% | 19.02B | |
-20.21% | 15.83B | |
-20.29% | 15.32B | |
-47.37% | 14.88B | |
+60.46% | 14.82B | |
+4.88% | 14.1B |